4D Molecular Therapeutics (FDMT) Gains from Sales and Divestitures (2024 - 2026)
4D Molecular Therapeutics (FDMT) reported Gains from Sales and Divestitures of $51779.0 for Q1 2026, up 132.87% year-over-year from $22235.0 in Q1 2025, and down 67.28% quarter-over-quarter from $158231.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Gains from Sales and Divestitures (2024 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 3 years of Gains from Sales and Divestitures data on file, last reported at $51779.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $51779.0, up 132.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $51779.0 (up 132.87% YoY), and the FY2025 annual result was $158231.0, up 199.2% from the prior year.
- Gains from Sales and Divestitures eased to $51779.0 in Q1 2026 per FDMT's latest filing, from $158231.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $158231.0 in Q4 2025 and troughed at $10996.0 in Q1 2024.
- A 3-year average of $59411.0 and a median of $51779.0 in 2026 frame the typical range for Gains from Sales and Divestitures.
- On a YoY basis, Gains from Sales and Divestitures climbed as much as 249.59% in 2025 and fell as far as 102.21% in 2025.
- A 3-year view of Gains from Sales and Divestitures shows it stood at $52884.0 in 2024, then surged by 199.2% to $158231.0 in 2025, then sank by 67.28% to $51779.0 in 2026.
- Business Quant data shows FDMT's Gains from Sales and Divestitures at $51779.0 in Q1 2026, $158231.0 in Q4 2025, and $113785.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51,779.00 |
| Mar 31, 2026 | 51,779.00 |
| Dec 31, 2025 | 158,231.00 |
| Dec 31, 2025 | 158,231.00 |
| Sep 30, 2025 | 113,785.00 |
| Sep 30, 2025 | 113,785.00 |
| Jun 30, 2025 | 70,278.00 |
| Jun 30, 2025 | 70,278.00 |
| Mar 31, 2025 | 22,235.00 |
| Mar 31, 2025 | 22,235.00 |
| Dec 31, 2024 | 52,884.00 |
| Dec 31, 2024 | 52,884.00 |
| Sep 30, 2024 | 32,548.00 |
| Sep 30, 2024 | 32,548.00 |
| Jun 30, 2024 | 21,963.00 |
| Jun 30, 2024 | 21,963.00 |
| Mar 31, 2024 | 10,996.00 |
| Mar 31, 2024 | 10,996.00 |